Across TCGA pan-cancer cohorts, NF1P9 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated NF1P9 data layer compared with 18 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher NF1P9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NF1P9 expression acts as an unfavorable survival marker.
SKCM are the cancer types where NF1P9 Mutation most reproducibly stratifies survival.